A groundbreaking international clinical trial has been testing an implanted adaptive deep brain stimulation (aDBS) device as a treatment therapy for Parkinson’s.
On Monday, the FDA approved Medtronic plc’s (NYSE:MDT) BrainSense Adaptive deep brain stimulation (aDBS) and BrainSense Electrode Identifier (EI) for patients with Parkinson’s disease. Deep brain ...
New closed-loop system self-adjusts DBS therapy to individual brain activity in real time; the largest commercial launch of brain-computer interface technology ever There is no cure for debilitating ...
European approval introduces the world's only closed-loop DBS system with real-time, self-adjusting brain stimulation for people with Parkinson's disease For 30 years, people with Parkinson's disease ...
DUBLIN, Oct. 9, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that BrainSense™ Adaptive Deep Brain Stimulation (aDBS) – the world's first ...
Personalized, adaptive deep brain stimulation (aDBS) is safe and effective for controlling motor symptoms over 10 months in adults with Parkinson’s disease (PD), new research showed. The ADAPT-PD ...
Medtronic is offering a peek into its ongoing, at-home trial of people with Parkinson’s disease being treated with adaptive deep brain stimulation, a technology that’s currently under review at the ...
Medtronic has received approval from the US Food and Drug Administration (FDA) for BrainSense, its adaptive deep brain stimulation (aDBS) therapy for patients living with Parkinson’s disease. The ...
New closed-loop system self-adjusts DBS therapy to individual brain activity in real time; the largest commercial launch of brain-computer interface technology ever GALWAY, Ireland, Feb. 24, 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results